PBSV Stock Pharma-Bio Serv (PBSV, $0.51) RSI Indicator left the oversold zone on August 14, 2025

GET DAILY SIGNALS

Get AI intraday signals

PBSV - Pharma-Bio Serv, Inc.

RSI signal

View

Odds of UP Trend

Price: $0.51125

Daily change: -$0.08875 (-14.79%)

Daily volume: 200

Capitalization: $11.7M

Industry: Services to the Health Industry

PBSV's RSI Oscillator ascending out of oversold territory

The RSI Oscillator for PBSV moved out of oversold territory on August 15, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In of the 23 cases the stock moved higher. This puts the odds of a move higher at .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 04, 2025. You may want to consider a long position or call options on PBSV as a result. In of 148 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

PBSV moved above its 50-day moving average on September 04, 2025 date and that indicates a change from a downward trend to an upward trend.

PBSV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Aroon Indicator for PBSV entered a downward trend on August 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PBSV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.135) is normal, around the industry mean (21.100). P/E Ratio (20.231) is within average values for comparable stocks, (81.703). PBSV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.758). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.429) is also within normal values, averaging (104.963).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PBSV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.